| 5.05 -0.44 (-8.01%) | 12-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.85 | 1-year : | 11.51 |
| Resists | First : | 6.72 | Second : | 9.85 |
| Pivot price | 2.36  |
|||
| Supports | First : | 1.64 | Second : | 1.37 |
| MAs | MA(5) : | 3.32 |
MA(20) : | 2.2 |
| MA(100) : | 2.12 |
MA(250) : | 2.57 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 56.4  |
D(3) : | 63.1 |
| RSI | RSI(14): 82.6 |
|||
| 52-week | High : | 9.85 | Low : | 1.1 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SERA ] has closed above the upper band by 8.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 570.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.67 - 5.7 | 5.7 - 5.72 |
| Low: | 4.65 - 4.68 | 4.68 - 4.7 |
| Close: | 5 - 5.05 | 5.05 - 5.09 |
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Thu, 07 Dec 2023
Sera Prognostics Inc (SERA) is up 2.91% Thursday In Premarket Trading - InvestorsObserver
Thu, 07 Dec 2023
While institutions invested in Sera Prognostics, Inc. (NASDAQ:SERA) benefited from last week's 183% gain, retail ... - Yahoo Finance
Wed, 06 Dec 2023
Top Midday Gainers -December 06, 2023 at 02:28 pm EST - Marketscreener.com
Wed, 06 Dec 2023
Sector Update: Health Care -December 06, 2023 at 02:02 pm EST - Marketscreener.com
Wed, 06 Dec 2023
Why Is Preterm Birth Risk Kit Focused Sera Prognostics Stock Trading Higher Today? - Sera Prognostics (NA - Benzinga
Wed, 06 Dec 2023
Sera Prognostics shares rocket 160% on PreTRM study update (SERA) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 2.019e+007 (%) |
| Held by Institutions | 15 (%) |
| Shares Short | 237 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -19 % |
| Return on Assets (ttm) | 485.7 % |
| Return on Equity (ttm) | -24.8 % |
| Qtrly Rev. Growth | 330000 % |
| Gross Profit (p.s.) | -178.28 |
| Sales Per Share | -143.8 |
| EBITDA (p.s.) | 258621 |
| Qtrly Earnings Growth | -1.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -28 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.04 |
| Price to Cash Flow | 0.6 |
| Dividend | 0 |
| Forward Dividend | 216850 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|